… immunotherapy, and the introduction of immune checkpoint inhibitors has brought fundamental
changes to the treatment of HCC. Programmed cell death protein 1 (PD-1… , we focused on …

… carcinoma (HCC) treated with programmed cell death 1 (PD-1) inhibitors. We aimed to …
this study, 10 (14·49%) patients with advanced HCC treated with anti-PD-1 immunotherapy …

… This indicated that neoadjuvant PD-1-targeted immunotherapy plus tyrosine kinase … proteins
cytotoxic T-lymphocyte- associated-4 (CTLA-4) and programmed cell death protein 1 (PD-1) …

… based treatments in hepatocellular carcinoma (HCC) has not been clearly demonstrated. In
this study, we focused on the infiltration and programmed death ligand 1 (PD-L1) expression …

… pembrolizumab, has generated encouraging results in phase Ib and is currently being tested
in phase III trials. Here, we aimed … line therapy in advanced hepatocellular carcinoma (HCC)…

… Another phase 2 trial using the anti-PD-1 antibody pembrolizumab showed an ORR of 17% …
mitogen-activated protein kinase and PI3K-Akt signaling [29], we specifically focused on any …

… intermediate stage or when given to prevent recurrence after liver resection or ablation (4). …
Immunotherapies targeting the programmed cell death 1 (PD-1) receptor protein blockade …

… load dictate the potential benefit from PD-1/PD-L1 targeting. … In our study, benefits to
PD-1/PD-L1 targeting were seen in … absolute clinical resistance to immunotherapy. We have noted …

… trial) in advanced hepatocellular carcinoma has recently been … and pembrolizumab, both
programmed cell death-1 (PD-1) … targeted drugs after progression on immunotherapy [67,68], …

… combined with programmed cell death protein-1 (PD-1) inhibitors … aimed to compare the
efficacy of HAIC combined with PD-1 … immunotherapy (14). Lenvatinib inhibits multiple receptor …